Removal of serine proteases by treatment with finely divided silicon dioxide
View Patent ↗The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
1. A method for preparing an inter-alpha-trypsin inhibitor (IαI) composition having a reduced amount of a serine protease or a serine protease zymogen, the method comprising the steps of:
(a) contacting a blood-plasma derived solution containing IαI and at least one serine protease with from 0.01 grams to 10 grams finely divided silicon dioxide (SiO 2 ) per gram protein under conditions suitable to bind the IαI and at least one serine protease, the conditions including a pH of from 4.0 to 7.0 and a conductivity of from 0.1 mS/cm to 2.0 mS/cm;
(b) separating the SiO 2 from the composition;
(c) eluting the serine protease or serine protease zymogen from the SiO 2 under conditions in which at least 50% of the IαI remains bound, the conditions including a pH of from 5.0 to 7.0 and a conductivity of less than 5 mS/cm; and
(d) eluting the IαI from the SiO 2 under conditions including a pH of from 7.0 to 8.0 and a conductivity of at least 2 mS/cm.
2. A method for preparing an inter-alpha-trypsin inhibitor (IαI) composition having a reduced amount of a serine protease or a serine protease zymogen, the method comprising the steps of:
(a) contacting a blood-plasma derived solution containing IαI and at least one serine protease with from 0.01 grams to 10 grams finely divided silicon dioxide (SiO 2 ) per gram protein under conditions suitable to bind the IαI and at least one serine protease, the conditions including a pH of from 4.0 to 7.0 and a conductivity of from 0.1 mS/cm to 2.0 mS/cm;
(b) separating the SiO 2 from the composition; and
(c) eluting the IαI from the SiO 2 under conditions in which at least 50% of the serine protease or serine protease zymogen remains bound to the SiO 2 , the conditions including a pH of from 7.0 to 8.0 and a conductivity of no more than 10 mS/cm.
3. A method for preparing an inter-alpha-trypsin inhibitor (IαI) composition having a reduced amount of a serine protease or a serine protease zymogen, the method comprising the steps of:
(a) contacting a blood-plasma derived solution containing IαI and at least one serine protease with from 0.01 grams to 10 grams finely divided silicon dioxide (SiO 2 ) per gram protein under conditions suitable to bind the IαI but not at least 50% of the at least one serine protease or serine protease zymogen, the conditions including a pH of from 7.0 to 9.0 and a conductivity of at least 10 mS/cm;
(b) separating the SiO 2 from the composition; and
(c) eluting the IαI from the SiO 2 under conditions including a pH of from 7.0 to 9.0 and a conductivity of less than 10 mS/cm.
4. A method for preparing an inter-alpha-trypsin inhibitor (IαI) composition having a reduced amount of a serine protease or a serine protease zymogen, the method comprising the steps of:
(a) contacting a blood-plasma derived solution containing inter-alpha-trypsin inhibitor (IαI) and at least one serine protease with from 0.01 grams to 10 grams finely divided silicon dioxide (SiO 2 ) per gram protein under conditions suitable to bind the serine protease or serine protease zymogen but not at least 50% of the inter-alpha-trypsin inhibitor (IαI), the conditions including a pH of from 7.0 to 9.0 and a conductivity of less than 10 mS/cm; and
(b) separating the SiO 2 from the composition.
5. The method of claim 1 , wherein the composition is contacted with SiO 2 at a final concentration of at least 1 g SiO 2 /g protein.
6. The method of claim 5 , wherein the composition is contacted with SiO 2 at a final concentration of at least 2 g SiO 2 /g protein.
7. The method of claim 5 , wherein the composition is contacted with SiO 2 at a final concentration of at least 2.5 g SiO 2 /g protein.
8. The method of claim 1 , wherein the serine protease or serine protease zymogen is Factor XI.
9. The method of claim 1 , wherein the serine protease or serine protease zymogen is Factor XII.
10. The method of claim 1 , wherein the serine protease or serine protease zymogen is Factor XIa.
11. The method of claim 1 , wherein the serine protease or serine protease zymogen is Factor XIIa.
12. The method of claim 1 , wherein the finely divided silicon dioxide (SiO 2 ) is fumed silica.
13. The method of claim 1 , wherein the conditions in step (c) include a pH of from 6.0±0.5.
14. The method of claim 1 , wherein the conditions in step (c) include a pH of rom 6.0±0.2.
15. The method of claim 2 , wherein the conditions in step (c) include a conductivity of about 6.0.
16. The method of claim 3 , wherein the conditions in step (a) include a conductivity of at least 20 mS/cm.
17. The method of claim 4 , wherein the conditions in step (a) include a conductivity of about 6.0.
18. The method of claim 2 , wherein the finely divided silicon dioxide (SiO 2 ) is fumed silica.
19. The method of claim 3 , wherein the finely divided silicon dioxide (SiO 2 ) is fumed silica.
20. The method of claim 4 , wherein the finely divided silicon dioxide (SiO 2 ) is fumed silica.